SLS
NASD SELLAS Life Sciences Group, Inc.$11.37 ↓ -0.94 (-7.64%) Trading Down from the previous close of $12.31, $0.88 below the day’s high of $12.25
- YTD change
- +201.59%
- vs 20-day SMA
- -7.66%
- vs 200-day SMA
- +47.93%
Price ranges
Price & Performance
+8.10 (+192.40%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.9% away from all-time highs of $11,709.00
- SLS is up 202% since the beginning of the year
- SLS is up 573% over the past 12 months
- SLS is down 14% over the past 1 month
- 32% of all SLS investors are betting against SLS
SLS reads not so good: price sits above one of the two key moving averages, the 12-month move is +628.4%.
- Previous minute
- +$0.00
- Last hour
- -$0.31
- Last 5 days
- -1.30%
- vs 8-day SMA
- -3.14%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.